The CD36-PPARγ Pathway in Metabolic Disorders.

Loïze Maréchal, Maximilien Laviolette, Amélie Rodrigue-Way, Baly Sow, Michèle Brochu, Véronique Caron, André Tremblay
Author Information
  1. Loïze Maréchal: Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. loize.marechal@umontreal.ca.
  2. Maximilien Laviolette: Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. maximilien.laviolette-brassard@umontreal.ca.
  3. Amélie Rodrigue-Way: Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. amelierway@aol.com.
  4. Baly Sow: Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. baly.sow@umontreal.ca.
  5. Michèle Brochu: Department of Physiology, Faculty of Medicine, University of Montreal, Montréal, QC H3T 1J4, Canada. michele.brochu@umontreal.ca.
  6. Véronique Caron: Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. veronique.caron.4@gmail.com.
  7. André Tremblay: Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. andre.tremblay.1@umontreal.ca. ORCID

Abstract

Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating metabolic disorders with the current use of thiazolidinediones to improve insulin resistance in diabetic patients. The recent identification of growth hormone releasing peptides (GHRP) as potent inducers of PPARγ through activation of the scavenger receptor CD36 has defined a novel alternative to regulate essential aspects of lipid and energy metabolism. Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here. The response of PPARγ coactivator PGC-1 is also discussed in these effects. The identification of the GHRP-CD36-PPARγ pathway in controlling various tissue metabolic functions provides an interesting option for metabolic disorders.

Keywords

References

  1. FASEB J. 2005 Nov;19(13):1869-71 [PMID: 16123174]
  2. Br J Pharmacol. 2001 Sep;134(1):143-9 [PMID: 11522606]
  3. J Cardiovasc Pharmacol. 1998 Aug;32(2):260-5 [PMID: 9700988]
  4. Nat Rev Mol Cell Biol. 2012 Mar 14;13(4):213-24 [PMID: 22414897]
  5. Adipocyte. 2015 Jan 26;4(3):161-80 [PMID: 26257990]
  6. Ann N Y Acad Sci. 2001 Dec;947:224-8 [PMID: 11795270]
  7. Endocrinology. 2006 Mar;147(3):1508-16 [PMID: 16357043]
  8. Cardiovasc Res. 2006 Jan;69(1):26-35 [PMID: 16219302]
  9. J Clin Endocrinol Metab. 2000 Oct;85(10):3803-7 [PMID: 11061542]
  10. Am J Health Syst Pharm. 2000 May 1;57(9):834 [PMID: 10840515]
  11. Mol Genet Metab. 2011 Apr;102(4):389-98 [PMID: 21262584]
  12. Endocrinology. 2017 Oct 1;158(10 ):3174-3187 [PMID: 28977588]
  13. Arch Pediatr. 2018 Apr;25(3):177-181 [PMID: 29576254]
  14. Nature. 1999 Dec 9;402(6762):656-60 [PMID: 10604470]
  15. Trends Cardiovasc Med. 2004 Jan;14(1):8-12 [PMID: 14720468]
  16. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):7981-7986 [PMID: 28630339]
  17. Hum Mol Genet. 2008 Jun 1;17(11):1695-704 [PMID: 18305138]
  18. J Biol Chem. 2000 Jun 16;275(24):18527-33 [PMID: 10748014]
  19. Nat Med. 2013 May;19(5):557-66 [PMID: 23652116]
  20. Mol Endocrinol. 2006 Dec;20(12 ):3165-78 [PMID: 16959872]
  21. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):348-54 [PMID: 19632256]
  22. Cell. 2006 Jan 13;124(1):35-46 [PMID: 16413480]
  23. Annu Rev Biochem. 2017 Aug 25;: [PMID: 28841344]
  24. PPAR Res. 2008;2008:364784 [PMID: 18288286]
  25. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):230-9 [PMID: 14592855]
  26. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1333-9 [PMID: 10323787]
  27. Cell. 1994 Dec 30;79(7):1147-56 [PMID: 8001151]
  28. Pediatr Rev. 2016 May;37(5):193-202 [PMID: 27139327]
  29. Sci Signal. 2009 May 26;2(72):re3 [PMID: 19471024]
  30. Mol Cell. 2001 Jan;7(1):161-71 [PMID: 11172721]
  31. J Manag Care Pharm. 2012 Apr;18(3):225-33 [PMID: 22468731]
  32. Ann Intern Med. 2016 Sep 6;165(5):305-15 [PMID: 27322798]
  33. J Clin Endocrinol Metab. 2010 Jul;95(7):3400-10 [PMID: 20427507]
  34. Am Heart J. 2012 Nov;164(5):672-80 [PMID: 23137497]
  35. Growth Horm IGF Res. 1998 Apr;8 Suppl B:149-52 [PMID: 10990152]
  36. Endocr Rev. 2005 May;26(3):346-60 [PMID: 15814848]
  37. Nature. 2006 Dec 14;444(7121):847-53 [PMID: 17167472]
  38. J Clin Med. 2016 Jun 23;5(7):null [PMID: 27348010]
  39. Cell. 1998 Apr 17;93(2):229-40 [PMID: 9568715]
  40. Int J Mol Med. 2003 Sep;12(3):279-87 [PMID: 12883642]
  41. N Engl J Med. 2004 Sep 9;351(11):1106-18 [PMID: 15356308]
  42. Trends Endocrinol Metab. 2012 Feb;23(2):65-72 [PMID: 22154484]
  43. Curr Opin Clin Nutr Metab Care. 2011 Nov;14(6):527-34 [PMID: 21912245]
  44. J Geriatr Cardiol. 2014 Sep;11(3):253-8 [PMID: 25278975]
  45. Eur J Pharmacol. 1997 Sep 10;334(2-3):201-7 [PMID: 9369349]
  46. J Investig Med. 2016 Aug;64(6):1082-6 [PMID: 27194746]
  47. Mol Endocrinol. 2011 Sep;25(9):1600-11 [PMID: 21719535]
  48. Eur J Biochem. 1996 Jul 1;239(1):1-7 [PMID: 8706692]
  49. J Clin Invest. 1996 Jun 1;97(11):2553-61 [PMID: 8647948]
  50. Toxicol Lett. 2010 Jun 2;195(2-3):135-41 [PMID: 20307632]
  51. J Clin Invest. 2000 Apr;105(8):1049-56 [PMID: 10772649]
  52. Curr Opin Pharmacol. 2006 Apr;6(2):142-7 [PMID: 16483844]
  53. J Biol Chem. 1997 Dec 12;272(50):31693-9 [PMID: 9395511]
  54. Lancet. 2010 Jan 16;375(9710):181-3 [PMID: 20109902]
  55. Br J Nutr. 2018 Feb;119(4):472-478 [PMID: 29446339]
  56. J Clin Invest. 1995 Oct;96(4):1859-65 [PMID: 7560077]
  57. Endocrinology. 1996 Dec;137(12):5284-9 [PMID: 8940347]
  58. Trends Endocrinol Metab. 2006 Jan-Feb;17 (1):13-8 [PMID: 16309920]
  59. Pharmacol Rev. 2014 Oct;66(4):984-1001 [PMID: 25107984]
  60. Br Med Bull. 2018 Mar 9;:null [PMID: 29534172]
  61. Science. 1996 Aug 16;273(5277):974-7 [PMID: 8688086]
  62. J Biol Chem. 2008 May 16;283(20):13578-85 [PMID: 18353783]
  63. Nutr Res Rev. 2009 Dec;22(2):137-47 [PMID: 19737436]
  64. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4543-7 [PMID: 15070754]
  65. Cell. 1995 Dec 15;83(6):835-9 [PMID: 8521507]
  66. Circ Res. 2002 May 3;90(8):844-9 [PMID: 11988484]
  67. Nature. 2005 Sep 29;437(7059):759-63 [PMID: 16127449]
  68. J Clin Endocrinol Metab. 1994 Mar;78(3):693-8 [PMID: 8126144]
  69. Endocr Rev. 2006 Dec;27(7):728-35 [PMID: 17018837]
  70. Physiol Rep. 2018 Feb;6(4):null [PMID: 29446246]
  71. Peptides. 2010 Apr;31(4):630-8 [PMID: 19931584]
  72. Eur J Endocrinol. 2009 Dec;161(6):861-70 [PMID: 19773372]
  73. Cell. 2007 Apr 20;129(2):251-62 [PMID: 17448988]
  74. Curr Drug Discov Technol. 2015 ;12 (2):90-116 [PMID: 26135857]
  75. J Clin Invest. 2006 Mar;116(3):615-22 [PMID: 16511594]
  76. PLoS One. 2009 Nov 04;4(11):e7728 [PMID: 19888469]
  77. Prog Lipid Res. 2009 Sep;48(5):257-74 [PMID: 19409927]
  78. Int Heart J. 2017 Apr 6;58(2):257-263 [PMID: 28321024]
  79. Sex Med Rev. 2018 Jan;6(1):45-53 [PMID: 28400207]
  80. Biochim Biophys Acta. 2010 Nov;1803(11):1298-307 [PMID: 20637247]
  81. Mol Cell Biol. 2001 Nov;21(22):7558-68 [PMID: 11604492]
  82. J Clin Invest. 2006 Mar;116(3):590-7 [PMID: 16511591]
  83. Endocrine. 2015 Jun;49(2):307-23 [PMID: 25645463]
  84. Nature. 2008 Jul 24;454(7203):470-7 [PMID: 18650918]
  85. N Engl J Med. 2010 May 6;362(18):1675-85 [PMID: 20427778]
  86. Eur Heart J. 2008 Dec;29(24):2959-71 [PMID: 18775919]
  87. Eur J Pediatr. 2011 Apr;170(4):483-92 [PMID: 20957391]
  88. Biochem Biophys Res Commun. 2006 Feb 3;340(1):111-7 [PMID: 16364246]
  89. J Clin Endocrinol Metab. 2007 Jan;92(1):264-9 [PMID: 17062757]
  90. Endocr Rev. 2003 Feb;24(1):78-90 [PMID: 12588810]
  91. J Biol Chem. 1999 Jul 2;274(27):19055-62 [PMID: 10383407]
  92. J Clin Endocrinol Metab. 1998 Apr;83(4):1186-9 [PMID: 9543138]
  93. Trends Endocrinol Metab. 2009 Oct;20(8):380-7 [PMID: 19748282]
  94. Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1418-23 [PMID: 17229846]
  95. Cell. 2004 Oct 15;119(2):157-67 [PMID: 15479634]
  96. Biochem Genet. 2012 Feb;50(1-2):103-11 [PMID: 22113854]
  97. Endocrinology. 2004 Jan;145(1):234-42 [PMID: 14551228]
  98. Prog Lipid Res. 2006 Mar;45(2):120-59 [PMID: 16476485]
  99. J Endocrinol. 2005 Jan;184(1):249-56 [PMID: 15642801]
  100. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56 [PMID: 15181022]
  101. Life Sci. 1994;54(18):1321-8 [PMID: 7910650]
  102. Cell Metab. 2014 Oct 7;20(4):573-91 [PMID: 25242225]
  103. Curr Diab Rep. 2009 Jun;9(3):215-20 [PMID: 19490823]
  104. Nat Med. 2004 Apr;10(4):355-61 [PMID: 15057233]
  105. Clin Endocrinol (Oxf). 1995 Nov;43(5):631-5 [PMID: 8548949]
  106. J Atheroscler Thromb. 2012;19(3):263-75 [PMID: 22075538]
  107. Cell Signal. 2007 May;19(5):1011-22 [PMID: 17229547]
  108. Biochim Biophys Acta. 2016 Oct;1861(10 ):1442-9 [PMID: 27004753]
  109. Semin Cell Dev Biol. 2012 Aug;23(6):631-9 [PMID: 22273692]
  110. Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1702-11 [PMID: 16728653]
  111. Antioxidants (Basel). 2018 Mar 27;7(4):null [PMID: 29584624]
  112. Circulation. 2005 Nov 8;112(19):2986-92 [PMID: 16260640]
  113. Free Radic Biol Med. 2016 Nov;100:153-163 [PMID: 27352979]
  114. Front Physiol. 2017 Dec 06;8:1006 [PMID: 29270130]
  115. Biochim Biophys Acta. 2009 Mar;1791(3):212-9 [PMID: 19159696]
  116. J Clin Invest. 2001 Sep;108(6):785-91 [PMID: 11560944]
  117. Lancet. 2007 Sep 29;370(9593):1103-4 [PMID: 17905146]
  118. Mol Cell. 1999 Oct;4(4):597-609 [PMID: 10549291]
  119. Endocrinology. 2007 Mar;148(3):1009-18 [PMID: 17138655]
  120. Drug Test Anal. 2014 Nov-Dec;6(11-12):1087-101 [PMID: 25312500]
  121. J Biol Chem. 1995 Jun 2;270(22):12953-6 [PMID: 7768881]
  122. Mol Cell Biochem. 2007 May;299(1-2):19-22 [PMID: 16670819]
  123. PLoS One. 2016 Feb 26;11(2):e0149730 [PMID: 26918825]
  124. Front Pharmacol. 2011 Mar 18;2:14 [PMID: 21687509]
  125. FASEB J. 2014 Apr;28(4):1910-23 [PMID: 24371122]
  126. Diabetologia. 2007 Jun;50(6):1127-39 [PMID: 17393135]
  127. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17 ):6472-7 [PMID: 15087503]
  128. Eur J Clin Pharmacol. 1994;46(5):421-5 [PMID: 7957536]
  129. Annu Rev Biochem. 2008;77:289-312 [PMID: 18518822]
  130. Endocr Rev. 2004 Jun;25(3):426-57 [PMID: 15180951]
  131. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 [PMID: 14660788]
  132. J Clin Endocrinol Metab. 2002 Jun;87(6):2988 [PMID: 12050285]
  133. Proc Natl Acad Sci U S A. 1979 Jan;76(1):333-7 [PMID: 218198]
  134. Hum Mol Genet. 2004 Oct 1;13(19):2197-205 [PMID: 15282206]
  135. Mol Cell. 2003 Jan;11(1):25-33 [PMID: 12535518]
  136. Sci Rep. 2017 Oct 12;7(1):13017 [PMID: 29026190]
  137. Diabetes. 2001 Aug;50(8):1863-71 [PMID: 11473050]
  138. Am J Physiol Regul Integr Comp Physiol. 2015 Feb 1;308(3):R188-98 [PMID: 25477422]
  139. Endocrinology. 1999 Sep;140(9):4024-31 [PMID: 10465272]

MeSH Term

Animals
CD36 Antigens
Drug Discovery
Energy Metabolism
Fatty Acids
Humans
Insulin Resistance
Metabolic Diseases
Oligopeptides
PPAR gamma
Signal Transduction

Chemicals

CD36 Antigens
Fatty Acids
Oligopeptides
PPAR gamma
hexarelin

Word Cloud

Created with Highcharts 10.0.0PPARγreceptorenergymetabolismmetabolicGHRProlenuclearreceptorsactivationdisordersinsulinresistanceidentificationscavengerCD36hexarelinatherosclerosisPGC-1Uncoveringbiologicalperoxisomeproliferator-activatedPPARsgreatlyadvancedknowledgetranscriptionalcontrolglucosepharmacologicalemergedefficientapproachtreatingcurrentusethiazolidinedionesimprovediabeticpatientsrecentgrowthhormonereleasingpeptidespotentinducersdefinednovelalternativeregulateessentialaspectslipidRecentadvancesemergingregulatingdownstreamactionsbenefitshepaticcholesterolbiosynthesisfatmitochondrialbiogenesissummarizedresponsecoactivatoralsodiscussedeffectsGHRP-CD36-PPARγpathwaycontrollingvarioustissuefunctionsprovidesinterestingoptionCD36-PPARγPathwayMetabolicDisordersPPARfattyacidoxidation

Similar Articles

Cited By